Contingency Management for Alcohol Use Disorders

• Sponsor: UConn Health (Other)
• Overall Status: Completed
• CT.gov ID: NCT02135237
• Collaborator: National Institute on Alcohol Abuse and Alcoholism (NIAAA) (NIH)
• Enrollment: 120
• Locations: 3
• Arms: 2
• Actual Duration (Months): 65
• Patients Per Site: 40
• Patients Per Site Per Month: 0.6

Study Details

Study Description

Brief Summary

Contingency management (CM) treatments are highly efficacious in improving outcomes of substance abusing patients. However, CM has rarely been applied to individuals with alcohol use disorders, primarily because of technological limitations in monitoring drinking. The Secure Continuous Remote Alcohol Monitor (SCRAMx®) is a new technology designed to continuously monitor alcohol consumption 24 hours a day for 7 days per week. The purpose of this study is to evaluate the efficacy of CM in reducing alcohol use using SCRAMx. In total, 120 alcohol abusing or dependent patients initiating outpatient treatment at community-based clinics will be randomly assigned to one of two conditions: standard care, or standard care plus CM with reinforcement based on results of SCRAMx readings. Compared with standard care, it is expected that CM will result in fewer drinking days and longer durations of continuous non-drinking days.

Condition or Disease	Intervention/Treatment	Phase
Alcohol Use Disorder; Contingency Management	Behavioral: Prize Contingency Management for Alcohol Abstinence; Behavioral: Standard Care	N/A

Study Design

• Study Type: Interventional
• Actual Enrollment: 120 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Contingency Management for Alcohol Use Disorders
• Actual Study Start Date: Jan 1, 2014
• Actual Primary Completion Date: Jun 1, 2019
• Actual Study Completion Date: Jun 1, 2019

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Control Group Standard Care	Behavioral: Standard Care
Experimental: Experimental Group Standard Care plus Prize Contingency Management for Alcohol Abstinence	Behavioral: Prize Contingency Management for Alcohol Abstinence; The systematic reinforcement of desired behaviors and the withholding of reinforcement for undesired behaviors; Behavioral: Standard Care

Outcome Measures

Primary Outcome Measures

1. longest duration of abstinence from alcohol [three months]

   objective report of alcohol use as measured by SCRAMx device

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• age 18 years or older

• current diagnosis of alcohol use disorder and self report of recent alcohol use

• pass an informed consent quiz

• agree to wear a SCRAMx monitor for 12 weeks

• have a standard SCRAMx compatible phone line in their home or agree to attend the clinic weekly for brief research visits/downloads

• agree to sign an off-campus property transfer form and return SCRAMx equipment

Exclusion Criteria:

• serious, uncontrolled psychiatric illness

• in recovery from pathological gambling

• have an unstable address

• intend to participate in activities incompatible with SCRAMx over the next 3 months

• are wearing SCRAMx for legal purposes

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	The Hospital of Central Connecticut at New Britain General	New Britain	Connecticut	United States	06050
2	Farrell Treatment Center	New Britain	Connecticut	United States	06051
3	Behavioral Health Network, Inc.	Springfield	Massachusetts	United States	01104

Sponsors and Collaborators

• UConn Health
• National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Investigators

• Principal Investigator: Sheila Alessi, Ph.D., UConn Health

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Sheila Alessi, Associate Professor, UConn Health
• ClinicalTrials.gov Identifier: NCT02135237
• Other Study ID Numbers: 12-204H-2; R01AA021446
• First Posted: May 9, 2014
• Last Update Posted: Nov 1, 2019
• Last Verified: Oct 1, 2019

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Alcoholism; Alcohol Drinking

Study Results

No Results Posted as of Nov 1, 2019